Kada ka saka NAD+ booster saboda kasala

Wannan sabon network meta‑analysis da aka wallafa a Frontiers in Nutrition (Gao da abokan aiki, Jami'ar Wasanni ta Beijing) ya duba tasirin ƙwayoyin da ke ƙara NAD+ – wato NMN, NR, NADH da nicotinamide (NAM) – kan yanayi daban‑daban na gajiya. Binciken ya nuna cewa ko da ɗayansu na ƙaruwa a juriya, babu wanda ya nuna canji a yadda mutane ke jin gajiya ko barci.

Binciken: Menene ainihin an yi?

Ƙungiyar ta aiwatar da bincike mai tsari da kuma meta‑analysis na cibiyar sadarwa (network meta‑analysis) bisa ga ƙa’idodin PRISMA‑NMA, sannan an yi rajista a PROSPERO (CRD420251237193). Hanyoyin meta‑analysis na cibiyar sadarwa na ba da damar kwatanta magunguna ko kari da ba a taɓa gwada su a kan juna ba kai tsaye.

• An haɗa: Gwaje‑gwaje 27 – 25 na su RCTs (randomized controlled trials) da 2 na quasi‑experimental
• Adadin mahalarta: Mutane 1,599 masu balaga
• Kayan da aka gwada: Nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), NADH, da nicotinamide (NAM)
• Fannonin sakamako: Gajiya da aka ji (perceived fatigue), ƙwarewar tunani (cognitive performance), juriya da ƙarfi (endurance & strength), ingancin rayuwa (QoL) da barci

Sakamako an bayyana su a matsayin standardized mean differences (SMD). SMD mafi girma na nufin tasiri mafi karfi, kuma an ƙayyade matsayi ta hanyar SUCRA scores. Marubutan sun bayyana cewa ba su da wata sha’awar kasuwanci ko kuɗi a cikin wannan bincike.

Menene ya fi aiki?

Marubutan sun jaddada cewa amsar “wace kari ce tafi aiki?” ta dogara da abin da kake son cimma.

Juriya – NMN yana jagoranta

NMN ya nuna ƙaruwar juriya da ke da alamar tasiri mai girma:

• Matsakaicin SMD (small effect): 0.66 (95 % CI 0.09–1.23)
• Matsakaicin girma (large effect): 1.02 (95 % CI 0.43–1.60)

A al’ada, SMD kusa da 1.0 ana ɗauka a matsayin tasiri mai girma, amma tazarar (confidence interval) na ƙasa tana ƙunshe da sifili, don haka sakamakon ba shi da ƙarfi sosai.

Ƙwarewar tunani – NADH ya fi tasiri

NADH ya ba da babbar fa’ida a kan ƙwarewar tunani, musamman a ƙungiyoyi da ke da nakasar kwakwalwa:

• SMD: 1.50 (95 % CI 0.82–2.19)

Duk da haka marubutan sun lura cewa wannan sakamakon yana da ƙarfi sosai kan wasu gwaje‑gwaje kaɗan; cire wasu gwaje‑gwaje na iya ƙara rage ko canza sakamakon. Saboda haka ba shi da tabbacin dindindin.

Ingancin rayuwa (QoL) – NMN yana da ƙaramin tasiri

QoL ya ɗan inganta, kuma NMN ne ya ba da gudunmawa mafi girma:

• Matsakaicin SMD: 0.56 (95 % CI 0.14–0.98)
• Karamar SMD: 0.45 (95 % CI 0.11–0.78)

Bisa ga waɗannan ƙima, fa’idar QoL ba ta da ƙarfi kamar ta juriya.

Ƙarfi – babu canji

Babu bambanci a karfin jiki (neuromuscular strength). Ko da NMN ya ƙara juriya, ba ya haɓaka ƙarfin jiki.

Gajiya da barci – babu wani magani da ya taimaka

Babban sakamakon binciken shine rashin nasara a gajiya da barci. Babu wani ɗayan kari da ya inganta gajiya da aka ji ko ƙara yawan bacci. An bayyana gajiya a matsayin lamari mai sassa‑sassa – ta haɗa tunani, jiki da zuciya – don haka sauyin ɓangare ɗaya ba lallai ne ya shafi sauran ba.

Yaya NR ke nan?

Duk da NR yana tsakanin sunayen da aka fi tattaunawa, takaitaccen sakamakon bai nuna nasara a kowane ɓangare ba. Wannan ba yana nufin NR ba zai yi aiki ba, sai dai a cikin takardun cikakkun binciken za a iya ganin inda NR ya tsaya.

Iyakoki da abubuwan da ya kamata a sani

• Gano karancin gwaje‑gwaje: Wasu gwaje‑gwaje ƙanana ne, wasu kuma ba a yi taƙama‑taƙama ba (quasi‑experimental).
• Bambancin mahalarta: Za a iya samun bambanci a shekarun, jinsi, nauyi da tsawon lokaci da aka ɗauka wajen gwaji, wanda ke ƙara rashin tabbas.
• Sakamakon SMD ba su da fassara ta kai tsaye: Marubutan ba su ba da ma’anar “kasa”, “matsakaici” ko “babba” ba; a al’ada, SMD 0.2 = ƙarami, 0.5 = matsakaici, 0.8 = babba.
• Dabarar NADH na tunani: An nuna tasiri ne a cikin ƙungiyoyi da ke da nakasar tunani kawai, ba a ga tasiri a tsakanin mutane marasa wannan matsala ba.
• Kwatanta kai tsaye ba zai yiwu ba: Nazarin cibiyar sadarwa yana amfana da bayanan da aka samu a baya; ba a yi gwajin kai tsaye tsakanin dukkan kari ba.

Abubuwan da za a iya amfani da su

Girma (dosis): Shaidar mafi ƙarfi ita ce girman NMN a juriya, inda tasiri ya fi girma a rukunin mafi girma. Takaitaccen ba ya fayyace gram; a cikin gwaje‑gwajen da suka wanzu, NMN yawanci ana ba da 250–1,200 mg a rana.

Lokaci: Takaitaccen ba ya ba da shawara kan tsawon lokacin amfani ko dangantaka da abinci/motsa jiki.

Waɗanda za su amfana:

• Mutanen da ke son haɓaka juriya (NMN).
• Wadanda ke neman ɗan ƙara ingancin rayuwa (QoL).
• Likitoci ko masu bincike da ke duban NADH ga ƙananan waɗanda ke da matsalar tunani.

Waɗanda ya kamata su yi hattara ko su guje shi:

• Duk wanda ke neman NAD+ booster don rage gajiya ko inganta barci – babu wani shaida.
• Mutanen da ke neman ƙara ƙarfi – karfafi ba ta canza ba.
• Matan da ke cikin ciki, masu shayarwa, ko masu ɗauke da wata cuta ko suna shan magani – su tuntuɓi likita kafin su yi amfani da wannan nau’in kari.

Gaba ɗaya

Binciken ya bayyana cewa tallace‑tallacen NAD+ boosters sun yi sama da sakamakon kimiyya. NMN shi ne mafi alƙawari wajen ƙara juriya, tare da ƙaramin fa’ida a ingancin rayuwa. NADH yana da alamar haɓaka tunani a cikin ƙungiyoyi da ke da nakasar kwakwalwa. Babu wani kari da ya nuna tasiri a kan gajiya da barci, ko ƙara ƙarfi. Marubutan sun ba da shawarar a yi amfani da dabaru masu inganci da la’akari da girma, yanayin mahalarta, da abin da ake son cimmawa kafin a yanke shawarar amfani da waɗannan kari.